News
NCEL
3.280
-0.74%
-0.025
Weekly Report: what happened at NCEL last week (0831-0904)?
Weekly Report · 09/07 09:55
Weekly Report: what happened at NCEL last week (0824-0828)?
Weekly Report · 08/31 10:01
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 08/27 12:05
Weekly Report: what happened at NCEL last week (0817-0821)?
Weekly Report · 08/24 10:01
Closing Bell Movers: Ross Stores up 8% after earnings beat
TipRanks · 08/20 23:35
NewcelX registers to sell 694K common shares for holders
TipRanks · 08/20 20:20
Weekly Report: what happened at NCEL last week (0810-0814)?
Weekly Report · 08/17 10:02
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 08/14 12:06
Weekly Report: what happened at NCEL last week (0803-0807)?
Weekly Report · 08/10 09:58
NewcelX Lines Up $1.4 Million Private Placement to Advance Type 1 Diabetes Program
TipRanks · 08/03 20:49
Weekly Report: what happened at NCEL last week (0727-0731)?
Weekly Report · 08/03 09:58
NewcelX Prices $1.4 Million Premium Equity Financing to Advance Type 1 Diabetes Cell Therapy
TipRanks · 07/31 13:27
NewcelX announces pricing of $1.4M equity financing
TipRanks · 07/31 13:21
NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
Barchart · 07/31 08:00
Weekly Report: what happened at NCEL last week (0720-0724)?
Weekly Report · 07/27 10:01
Weekly Report: what happened at NCEL last week (0713-0717)?
Weekly Report · 07/20 09:58
NewcelX announces Brazil patent for cell selection, enrichment technology
TipRanks · 07/15 13:15
NewcelX Issued Patent From Brazilian Patent And Trademark Office For Its Nnovative Cell Selection And Enrichment Technology
Benzinga · 07/15 13:01
NewcelX Price Target Announced at $23.00/Share by Laidlaw & Co.
Dow Jones · 07/13 11:38
NewcelX Initiated at Buy by Laidlaw & Co.
Dow Jones · 07/13 11:38
More
Webull provides a variety of real-time NCEL stock news. You can receive the latest news about NewcelX Ltd through multiple platforms. This information may help you make smarter investment decisions.
About NCEL
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.